surface coordination engineering of gold nanoclusters with sc 3 for selective fluorescent detection of pyridoxal 5 phosphate

Original title: “Surface coordination engineering of gold nanoclusters with Sc(3+) for selective fluorescent detection of pyridoxal 5'-phosphate.”

gemcitabine based versus fluoropyrimidine based chemotherapy and role of platinum combination for first line palliative systemic treatment in advanced ampullary adenocarcinoma

Original title: “Gemcitabine-Based versus Fluoropyrimidine-Based Chemotherapy and Role of Platinum Combination for First-Line Palliative Systemic Treatment in Advanced Ampullary Adenocarcinoma.”

multiple cervical vagus nerve schwannomas masquerading as abnormal lymph nodes in sonography a case report

Original title: “Multiple Cervical Vagus Nerve Schwannomas Masquerading as Abnormal Lymph Nodes in Sonography: A Case Report.”

renal limited thrombotic microangiopathy in infants a case series

Original title: “Renal-Limited Thrombotic Microangiopathy in Infants: A Case Series.”

primary splenic angiosarcoma presenting with unexplained anemia in a young adult a case report

Original title: “Primary splenic angiosarcoma presenting with unexplained anemia in a young adult: a case report.”

successful intracardiac repair of unrepaired tetralogy of fallot in a 51 year old woman a case report

Original title: “Successful intracardiac repair of unrepaired tetralogy of fallot in a 51-year-old woman: a case report.”

co occurrence of moyamoya syndrome and turner syndrome in a 4 year old sudanese girl a rare case report

Original title: “Co-occurrence of moyamoya syndrome and Turner syndrome in a 4-year-old Sudanese girl: a rare case report.”

extended follow up of cd19 car t cell therapy in connective tissue disease associated pulmonary arterial hypertension

Original title: “Extended follow-up of CD19 CAR T-cell therapy in connective tissue disease-associated pulmonary arterial hypertension.”

survival in congenital central hypoventilation syndrome cchs data from the european cchs consortium

Original title: “Survival in congenital central hypoventilation syndrome (CCHS): data from the European CCHS Consortium.”

generalized joint hypermobility in adolescent idiopathic scoliosis greater curve flexibility larger thoracic kyphosis but higher complication risk

Original title: “Generalized Joint Hypermobility in Adolescent Idiopathic Scoliosis: Greater Curve Flexibility, Larger Thoracic Kyphosis, but Higher Complication Risk.”

fatal prosthetic valve endocarditis after transcatheter tricuspid valve replacement specialist cardiac autopsy findings

Original title: “Fatal Prosthetic Valve Endocarditis After Transcatheter Tricuspid Valve Replacement: Specialist Cardiac Autopsy Findings.”

Initial findings show that the therapy reduced or eliminated disease signs in all recipients, sparking hopes that the treatment might be competitive with “ex vivo” medicines like Novartis’ Kymriah.

Original title: “Legend surges on early data for ‘in vivo’ lymphoma cell therapy”

Revolution Medicines stole the show at the 2026 American Society of Clinical Oncology meeting as full data from its pancreatic cancer drug lived up to expectations, while Summit and Akeso proved the PD-(L)1/VEGF mechanism and Eli Lilly showed that its in vivo CAR T bet is paying off.

Original title: “ASCO’s biggest winners showcased a new era of cancer innovation”

As a result, promising therapies that fall outside the ‘one pill, one disease’ framework are perpetually marginalized, not necessarily because they lack efficacy, but because they cannot readily produce the specific form of evidence the RCT paradigm was designed to generate. Third, the placebo effect, combined with the bias introduced when clinical trial observers know a patient is receiving treatment... As a result, promising therapies that fall outside the ‘one pill, one disease’ framework are perpetually marginalized, not necessarily because they lack efficacy, but because they cannot readily produce the specific form of evidence the RCT paradigm was designed to generate. Third, the placebo effect, combined with the bias introduced when clinical trial observers know a patient is receiving treatment, will make a therapy appear more effective than it actually is. A practical guide to spotting doctored research and finding the therapies that actually help If clinically significant results are obtained through observational trials, they must be viewed as the “best-available evidence” until a more costly large RCT affirms or refutes them. The most efficient tool we have to refine the practice of medicine is allowing clinicians in the field to figure out what works and then have their peers replicate those studies. During the AIDS crisis, doctors in practice found ways to use existing therapies to treat the disease, while academics in their ivory towers (with pharmaceutical partnerships) failed to produce results. Essentially, what this showed is that there was no correlation between a treatment’s efficacy and if it ended up in treatment guidelines. Rather, it was primarily a result of how profitable the therapy was (presumably because that propelled the lobbying necessary to get it approved), and more remarkably, the therapies developed by our robust clinical trial process were amongst the worst options available, which in part was due to the fact the committee which created America’s guidelines was selected by Fauci (who’d previously stonewalled every efficacious therapy for AIDS to push AZT through) and nearly everyone Fauci put on it had previously taken money from remdesivir’s manufacturer.

Original title: “How They Rig Clinical Trials — Leaving Millions Sick, Broke, and Gaslit”

Monthly rifampin-moxifloxacin-minocycline therapy lowers the risk for type 1 reactions in patients with Hansen disease, study shows. Researchers conducted a retrospective cohort study of 111 patients with biopsy- and polymerase chain reaction-confirmed HD treated at a Miami HD clinic between October 2010 and November 2025. The mean age of the patients was 52 years (range, 15-85 years); 62% were male; 40%-43% were Hispanic, 52%-56% were non-Hispanic, 9%-12% were Black or African American, and 84%-88% were White; 70% had multibacillary disease. Patients received either World Health Organization-recommended MDT (monthly rifampin and daily dapsone and clofazimine; n = 86, 77%), the global gold standard treatment, or monthly RMM therapy (n = 25, 23%); 11 (10%) patients later switched from MDT to monthly RMM (a single dose of rifampin, moxifloxacin, and minocycline). Borderline lepromatous or lepromatous leprosy disease status was associated with an increased risk for ENL (OR, 11.9; P < .001) compared with other disease types. “This study was the first to demonstrate a significantly lower risk of T1R [type 1 reactions] in patients receiving RMM vs MDT and no significant difference in ENL risk,” the authors of the study wrote. “While prospective, head-to-head trials are needed to establish the effectiveness and microbiological outcomes of RMM therapy in multibacillary disease,” they added, the study “provided some reassurance regarding its decreased risk of T1R, although this finding must be interpreted with caution given the limited sample size.” RMM has been recommended by the National Hansen’s Disease Program since 2025, although studies are limited. The primary outcomes were the occurrence of a type 1 reaction (which often leads to disability) or erythema nodosum leprosum (ENL). Type 1 reactions occurred in 56% of patients with a median onset of 2 months after initiating antibiotics, and ENL occurred in 33% of patients with a median onset of 1 month. Patients who received RMM therapy had a significantly lower risk for a type 1 reaction than those who received MDT (odds ratio [OR], 0.28; P = .047). Monthly RMM therapy was not associated with the risk for ENL compared with MDT (OR, 0.89, P = .86), and no significant differences were observed in the frequency of immunologic reactions, duration of symptoms, or immunosuppressant use. Borderline disease status was associated with an increased risk for type 1 reactions (OR, 8.48; P < .001) compared with either tuberculoid or lepromatous disease.

Original title: “Monthly Rifampin-Moxifloxacin-Minocycline Therapy Lowers Immune Reactions in Hansen Disease”

clinical effectiveness of efgartigimod in a broad population of patients with generalized myasthenia gravis subgroup analyses from a randomized double blind placebo controlled phase 3 trial adapt

Original title: “Clinical effectiveness of efgartigimod in a broad population of patients with generalized myasthenia gravis: subgroup analyses from a randomized, double‑blind, placebo‑controlled, phase 3 trial (ADAPT).”